Interestingly, in a cohort of patients with small cell lung carcinoma, one of the most aggressive tumors known, autoantibodies to ZIC2 are present in 28% of patients, and the presence of these autoantibodies is associated with less aggressive clinical parameters such as a better response to initial therapy [14]. This evidence concerns the gene ZIC2 and small cell lung carcinoma.